OBR Daily Commentary

forumImage

The IPAB: How Will It Change Medicare?

(Kaiser Health News) May 8, 2011 - It sounds like a new Apple product, but IPAB is actually a controversial board at the heart of a highly charged battle over Medicare, the federal health program for the elderly and disabled.

Thomas Marsland, MD (Posted: May 11, 2011)

quotesOf all the things in the health care reform bill the IPAB is perhaps the most scary. It puts in place a group of "appointed" individuals who are not responsible to anyone. They have unlimited authority and, taken to the worst case scenario, could result in total price controls. The IPAB is really not subject to any of the other checks and balances other areas of government are. Their potential to impact health care delivery could truly be catastrophic. quotes

Read Article arrow
Add Comment 1 Comment
forumImage

New Study Suggests Breast Cancer Treatments Lose Effectiveness Over Time

(CTRC/UT Health Science Center) May 9, 2011 - Some breast cancer treatments designed to reduce the risk of a recurrence may lose their effectiveness once the patient survives the first three-year danger zone, suggests a new study published online today in the Journal of Clinical Oncology.

(Posted: May 11, 2011)

quotesThis interesting comment outlines what we now know about differences in recurrence patterns based on tumor biology - with a relatively striking time based variation. The authors suggest that this implies that therapies delivered in the adjuvant setting, specifically chemotherapy, lose effectiveness over time. Indeed we need to understand the natural history of specific cancers, and even more importantly, appropriately individualize therapy to biology. However, patients with early stage breast cancer are living longer now than ever before, and patients with the most aggressive form of cancer are generally free of relapse if they survive without recurrence for 5 years. In contrast, patients with indolent, hormone receptor positive disease experience at least 50% of their relapse risk after 5 years. So, in fact, adjuvant therapy does not 'lose' its effectiveness. Instead, chemotherapy has its greatest impact on cancers likely to recur early. The later relapses may be better controlled by longer duration hormone therapy, perhaps given in sequence or intermittently to reduce development of resistance. Current clinical trial design must take this biologic heterogeneity into account.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Blood Pressure May Hint at Kidney Cancer Outcome

(U.S. News & World Report) May 5, 2011 - In people with advanced kidney cancer, blood pressure appears to indicate how well their medication is working, with high blood pressure linked to longer survival, new research shows.

Robert A. Figlin, MD., FACP (Posted: May 06, 2011)

quotesAlthough I am a co-author on this publication I wanted to take the opportunity to review the implications found in this retrospective study for practicing physicians and the pharmaceutical industry. We have demonstrated that hypertension as defined in this study may be an on target effect of Sunitinib, and as such may be a biomarker of who is likely to benefit. As in all retrospective analysis such as these it will be important for this observation to be validated prospectively. Studies are underway to do just that. If hypertension is a biomarker of benefit we as physicians and the industry that provides us with these molecules must determine their biology and assist the doctor and patient in their best management.Through further investigation will we be able to offer our patients the greatest chance for clinical benefit. Additionally, we can expect that other on target effects formerly thought as "side effects" of the drug may very well be an important indicator of who might benefit. Strategies to modify on target "side effects" must become part of the strategies for drug development in this era of targeted therapy for cancer.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...